CD274 and neoplasm: Collectively, our results indicate that BBR, either alone or combined with anti-PD-L1 antibody, enhances anti-tumor immunity and effectively inhibits H22 tumor progression, offering a novel therapeutic strategy for HCC and guiding future clinical applications of BBR.